Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

Heart

Volumn 103, Issue 19, 2017, Pages 1536-1542

  Brook, Robert D ^a   Anderson, Julie A ^b   Calverley, Peter M A ^c,d   Celli, Bartolome R ^e   Crim, Courtney ^f   Denvir, Martin A ^g   Magder, Sheldon ^h   Martinez, Fernando J ⁱ   Rajagopalan, Sanjay ^j   Vestbo, Jørgen ^k   Yates, Julie ^f   Newby, David E ^g  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j UNIVERSITY OF MARYLAND   (United States)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE; PLACEBO; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CHLOROBENZENE; DRUG COMBINATION; GLUCOCORTICOID;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; FOLLOW UP; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; BENZYL ALCOHOLS; CARDIOVASCULAR DISEASES; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TREATMENT OUTCOME;

EID: 85029700533     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-310897     Document Type: Article

References (21)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet 2012;380:2095-128.
2. Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010;80:112-9.
3. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-9.
4. Schneider C, Bothner U, Jick SS, et al. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010;25:253-60.
5. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-62.
6. Calverley PMA, Anderson JA, Celli B, et al; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:719-25.
7. Rothnie KJ, Smeeth L, Herrett E, et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart 2015;101:1103-10.
8. Rothnie KJ, Yan R, Smeeth L, et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015;5:e007824.
9. Maclay JD, MacNee W. Cardiovascular disease in COPD. Chest 2013;143:798-807.
10. Rajagopalan S, Brook RD. Mortality from myocardial infarction in chronic obstructive pulmonary disease: minding and mending the 'Gap'. Heart 2015;101:1085-6.
11. Woodruff PG. Double-edged sword? Long-acting bronchodilators in chronic obstructive pulmonary disease. JAMA Intern Med 2013;173:1184-5.
12. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-21.
13. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013;173:1175-85.
14. Xia N, Wang H, Nie X. Inhaled long-acting ?2-agonists do not increase fatal cardiovascular adverse events in COPD: a meta-analysis. PLoS One 2015;10:e0137904.
15. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013;41:1017-22.
16. Vestbo J, Anderson J, Brook RD, et al; SUMMIT Investigators. Fluticasone furoate and vilanterol in patients with chronic obstructive pulmonary disease at heightened cardiovascular risk. Lancet 2016;387:1817-26.
17. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50.
18. Halpin DM, Dahl R, Hallmann C, et al. Tiotropium HandiHaler(®) and Respimatrespimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis 2015;10:239-59.
19. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;(7):CD009285.
20. Wise RA, Anzueto A, Cotton D, et al; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491-501.
21. Yusuf S, Islam S, Chow CK, et al; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 2011;378:1231-43.